CY1105766T1 - Χρηση συνθεσεων που εμπepιεχουν ενα οιστρογονικο συστατικο για τη θepαπευτικη αγωγη και προληψη των μυοσκελετικων πονων - Google Patents

Χρηση συνθεσεων που εμπepιεχουν ενα οιστρογονικο συστατικο για τη θepαπευτικη αγωγη και προληψη των μυοσκελετικων πονων

Info

Publication number
CY1105766T1
CY1105766T1 CY20061101608T CY061101608T CY1105766T1 CY 1105766 T1 CY1105766 T1 CY 1105766T1 CY 20061101608 T CY20061101608 T CY 20061101608T CY 061101608 T CY061101608 T CY 061101608T CY 1105766 T1 CY1105766 T1 CY 1105766T1
Authority
CY
Cyprus
Prior art keywords
estrogenic component
prevention
group
musculoskeletal pain
inhibitors
Prior art date
Application number
CY20061101608T
Other languages
English (en)
Inventor
Herman Jan Tijmen Coelingh Bennink
Evert Johannes Bunschoten
Original Assignee
Pantarhei Bioscience B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pantarhei Bioscience B.V. filed Critical Pantarhei Bioscience B.V.
Publication of CY1105766T1 publication Critical patent/CY1105766T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Η παρούσα ανακάλυψη αφορά σε μία μέθοδο για τη θεραπευτική αγωγή ή την πρόληψη των μυοσκελετικών πόνων σε θηλαστικά τα οποία λαμβάνουν έναν καταστολέα οιστρογόνων που έχει επιλεγεί από την ομάδα που περιλαμβάνει τους αναστολείς της αρωματάσης, τα GnRH ανάλογα, τους αναστολείς της κυκλο-οξυ-γενάσης 2 (COX-2), τους αναστολείς της 17β-υδροξυστεροειδούς αφυδρογενάσης τύπου 1, τα προγεσταγόνα, τα αντι-οιστρογόνα και συνδυασμούς τους, η αναφερόμενη μέθοδος περιλαμβάνει τη χορήγηση μίας αποτελεσματικής ποσότητας ενός οιστρογονικού συστατικού, όπου το οιστρογονικό συστατικό επιλέγεται από την ομάδα που αποτελείται από: ενώσεις που αναπαριστώνται από τον ακόλουθο τύπο (1) όπου τα R1 R2, R3, R4 είναι ανεξαρτήτως ένα άτομο υδρογόνου, μία ομάδα υδροξυλίου ή μία ομάδα αλκοξυλίου με 1-5 άτομα άνθρακα· πρόδρομες ενώσεις ικανές να ελευθερώσουν μία ένωση που ακολουθεί τον παραπάνω τύπο όταν χρησιμοποιούνται στην παρούσα μέθοδο και μίγματα μίας ή περισσότερων από τις προαναφερόμενες ενώσεις και/ή προδρόμων ενώσεων.
CY20061101608T 2003-05-22 2006-11-08 Χρηση συνθεσεων που εμπepιεχουν ενα οιστρογονικο συστατικο για τη θepαπευτικη αγωγη και προληψη των μυοσκελετικων πονων CY1105766T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03076555 2003-05-22
EP04734005A EP1624878B1 (en) 2003-05-22 2004-05-19 Use of compositions comprising an estrogenic component for the treatment and prevention of musculoskeletal pain
PCT/NL2004/000354 WO2004103377A1 (en) 2003-05-22 2004-05-19 Use of compositions comprising an estrogenic component for the treatment and prevention of musculoskeletal pain

Publications (1)

Publication Number Publication Date
CY1105766T1 true CY1105766T1 (el) 2011-02-02

Family

ID=33462160

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101608T CY1105766T1 (el) 2003-05-22 2006-11-08 Χρηση συνθεσεων που εμπepιεχουν ενα οιστρογονικο συστατικο για τη θepαπευτικη αγωγη και προληψη των μυοσκελετικων πονων

Country Status (13)

Country Link
US (1) US20060276414A1 (el)
EP (1) EP1624878B1 (el)
CN (1) CN100431545C (el)
AT (1) ATE340580T1 (el)
CA (1) CA2526338C (el)
CY (1) CY1105766T1 (el)
DE (1) DE602004002591T9 (el)
DK (1) DK1624878T3 (el)
ES (1) ES2274456T3 (el)
PL (1) PL1624878T3 (el)
PT (1) PT1624878E (el)
SI (1) SI1624878T1 (el)
WO (1) WO2004103377A1 (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2299730T3 (es) * 2002-07-12 2008-06-01 Pantarhei Bioscience B.V. Composicion farmaceutica que comprende derivados de estetrol para el uso en la terapia del cancer.
US20080287408A1 (en) * 2007-05-14 2008-11-20 Drugtech Corporation Endometriosis treatment
KR20100068287A (ko) * 2007-09-17 2010-06-22 쁘레글렘 에스.아. 폐경기 전 여성의 에스트로겐 의존성 질환의 치료
DK2714712T3 (en) 2011-06-01 2016-12-05 Estetra Sprl A process for the preparation of intermediates estetrol
HUE029252T2 (en) 2011-06-01 2017-02-28 Estetra Sprl Process for the preparation of intermediates of estetrol
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS61812B1 (sr) * 2015-06-18 2021-06-30 Estetra Sprl Oralno-disperzibilna tableta koja sadrži estetriol
AU2016280863B2 (en) 2015-06-18 2021-04-01 Estetra Srl Orodispersible dosage unit containing an estetrol component
KR102662025B1 (ko) 2015-06-18 2024-05-02 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 에스테트롤 성분을 함유하는 구강분해성 투여 단위
MD3310346T2 (ro) 2015-06-18 2021-06-30 Estetra Sprl Comprimată orodispersabilă ce conține estetrol
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
EP3787632B1 (en) 2018-05-02 2022-05-25 Estetra SPRL Treatment regimen for the treatment of advanced oestrogen receptor positive breast cancer

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2834712A (en) * 1953-05-27 1958-05-13 American Home Prod Urinary estrogen compositions and methods for preparing them
US2753290A (en) * 1953-08-06 1956-07-03 Olin Mathieson Microbiological production of 7-and 15-hydroxy-progesterones
US3440320A (en) * 1964-06-18 1969-04-22 Mortimer D Sackler Chelated suppository and method of using same
US3487152A (en) * 1967-02-07 1969-12-30 Hoffmann La Roche Tablets containing 7 - chloro - 2 - methylamino - 5 - phenyl - 3h - 1,4 - benzodiazepine-4-oxide and conjugated estrogenic substances
US3608075A (en) * 1969-07-28 1971-09-21 American Home Prod Compositions and methods of treating the menopausal syndrome
YU243975A (en) * 1974-10-14 1982-06-30 Schering Ag Process for obtaining 7-hydroxyestradiols
FR2377419A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 11b-substitues 1,3,5 (10) trieniques, leur procede de preparation et leur application comme medicament
US4937238A (en) * 1986-03-04 1990-06-26 The Board Of Regents Of The University Of Nebraska Prevention of mammary carcinoma
US4762717A (en) * 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US5270172A (en) * 1991-04-26 1993-12-14 Dekk-Tek, Inc. Method to predict tumor response to therapy
US5468736A (en) * 1993-02-25 1995-11-21 The Medical College Of Hampton Road Hormone replacement therapy
US5811416A (en) * 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
US6613757B1 (en) * 1994-09-22 2003-09-02 Board Of Regents, The University Of Texas System Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy
US5672609A (en) * 1996-07-18 1997-09-30 Eli Lilly And Company Pyridine compounds, intermediates compositions and methods of use
US6170058B1 (en) * 1997-12-23 2001-01-02 Arcot Systems, Inc. Method and apparatus for cryptographically camouflaged cryptographic key storage, certification and use
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
US6291456B1 (en) * 1998-12-30 2001-09-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
GB0005257D0 (en) * 2000-03-03 2000-04-26 Pharmacia & Upjohn Spa Breast cancer hormonal therapy
RU2180570C1 (ru) * 2000-09-25 2002-03-20 Писаревский Юрий Леонидович Способ лечения болевого синдрома при дисфункциях височно-нижнечелюстного сустава у женщин
US6790979B2 (en) * 2002-04-17 2004-09-14 University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof

Also Published As

Publication number Publication date
PL1624878T3 (pl) 2007-01-31
CA2526338C (en) 2012-09-25
WO2004103377A1 (en) 2004-12-02
EP1624878B1 (en) 2006-09-27
DE602004002591D1 (de) 2006-11-09
PT1624878E (pt) 2007-01-31
SI1624878T1 (sl) 2007-02-28
DE602004002591T9 (de) 2008-01-03
ES2274456T3 (es) 2007-05-16
CN100431545C (zh) 2008-11-12
EP1624878A1 (en) 2006-02-15
CA2526338A1 (en) 2004-12-02
ATE340580T1 (de) 2006-10-15
CN1816340A (zh) 2006-08-09
US20060276414A1 (en) 2006-12-07
DE602004002591T2 (de) 2007-08-09
DK1624878T3 (da) 2007-01-08

Similar Documents

Publication Publication Date Title
CY1105766T1 (el) Χρηση συνθεσεων που εμπepιεχουν ενα οιστρογονικο συστατικο για τη θepαπευτικη αγωγη και προληψη των μυοσκελετικων πονων
SV2006002103A (es) Compuestos de aril- o heteroarilamida ortosustituidos ref. pc32242a
CY1105957T1 (el) Χρηση οιστρογονων ενωσεων σε συνδυασμο με ενωσεις προγεστογονου (progestogen) σε θepαπεια ορμονικης αντικαταστασης
SV2005002102A (es) Compuestos de metil-aril o heteroaril-amida sustituida ref. pc32241a
PA8610801A1 (es) Compuestos de aril o heteroaril amida
UY28674A1 (es) Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1
SG155967A1 (en) Hcv ns3-ns4a protease inhibition
NO20062617L (no) Anvendelse av glukosidase inhibitorer for terapi av mucovisidose
BR0014541A (pt) Compostos quìmicos
ATE256681T1 (de) N-heterozyklische derivate als nos inhibitoren
PL369108A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
ATE252097T1 (de) N-heterocyclische derivate als nos inhibitoren
IL184116A0 (en) Use of thiazolidinone derivatives as antiangiogenic agents
HK1081194A1 (en) 6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof
AR012878A1 (es) Un compuesto derivado de 5'-desoxicitidina, su uso, un proceso para fabricarlo, composiciones farmaceuticas que lo comprende, y un kit que comprende dicha composicion.
DK1511472T3 (da) Anvendelige forbindelser til behandling af Anthrax og hæmning af letalfaktor
BRPI0416289A (pt) 4-anilino-3-quinolinacarbonitrilas para o tratamento de leucemia mielógeno crÈnica (cml)
HUP0402341A2 (hu) Szubsztituált tiazol-2-ilaminokat tartalmazó készítmények rák kezelésére
DE602004018811D1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
DE60324401D1 (de) Iodierte triglycerid-derivate
IL150100A0 (en) Pharmaceutical compositions containing fused cyclic compounds
BR0212454A (pt) Composto, composição farmacêutica, métodos para o tratamento ou prevenção de distúrbios fisiológicos associados com um excesso de taquicininas e de dor ou inflamação, enxaqueca, êmese, neuralgia pós-terpética, depressão ou ansiedade, e, uso de um composto
HUP0401189A2 (hu) Új mandulasavszármazékok és felhasználásuk trombin inhibitorokként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
DE69527789D1 (de) Mittel zur behandlung von kachexie die im zusammenhang mit tumoren steht
TW200621740A (en) Compound for treating hepatitis B and composition thereof